INSULET CORPORATION Material Contracts
Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.
- 2023-06-12: Form 8-K; Exhibit 10.1; Description Fourth Amendment to Credit Agreement, dated June 9, 2023, among Insulet Corporation, Insulet MA Securities Corporation, Morgan Stanley Senior Funding, Inc., as administrative agent, swingline lender, and letter of credit issuer, and the other lenders party thereto..
- 2023-06-07: Form 8-K; Exhibit 10.1; Description Amendment Number 21, dated as of June 1, 2023, to the Supply Agreement by and between Amgen Inc. and Insulet Corporation.
- 2023-05-04: Form 8-K; Exhibit 10.1; Description Consulting Services Agreement by and between the Company and Bret Christensen dated May 2, 2023.
- 2023-02-24: Form 10-K; Exhibit 10.66; Description Form of Confidentiality, Non-Solicit, Non-Compete, and IP Assignment Agreement, by and between the Company and Employee (Jim Hollingshead and Dan Manea).
| Filed | Form | Exhibit | Description |
|---|
| 2023-06-12 | 8-K | 10.1 | Fourth Amendment to Credit Agreement, dated June 9, 2023, among Insulet Corporation, Insulet MA Securities Corporation, Morgan Stanley Senior Funding, Inc., as administrative agent, swingline lender, and letter of credit issuer, and the other lenders party thereto. |
|---|
| 2023-06-07 | 8-K | 10.1 | Amendment Number 21, dated as of June 1, 2023, to the Supply Agreement by and between Amgen Inc. and Insulet Corporation |
|---|
| 2023-05-04 | 8-K | 10.1 | Consulting Services Agreement by and between the Company and Bret Christensen dated May 2, 2023 |
|---|
| 2023-02-24 | 10-K | 10.66 | Form of Confidentiality, Non-Solicit, Non-Compete, and IP Assignment Agreement, by and between the Company and Employee (Jim Hollingshead and Dan Manea) |
|---|
| 2023-02-24 | 10-K | 10.59 | Amendment Number 20 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation, dated June 25, 2021 |
|---|
| 2023-02-24 | 10-K | 10.58 | Amendment Number 19 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation, dated July 13, 2020 |
|---|
| 2023-02-24 | 10-K | 10.57 | Amendment Number 18 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation, dated August 1, 2019 |
|---|
| 2023-02-24 | 10-K | 10.56 | Amendment Number 17 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation, dated April 1, 2019 |
|---|
| 2023-02-24 | 10-K | 10.55 | Amendment Number 15 to the Supply Agreement by and between Amgen Inc. and Insulet Corporation, dated July 12, 2017 |
|---|
| 2023-02-24 | 10-K | 10.54 | Manufacturing Services and Line Retention Agreement between Insulet Corporation and Flex Medical Sales and Marketing, Ltd., dated July 29, 2022 |
|---|
| 2023-02-24 | 10-K | 10.53 | Second Amendment to the Master Equipment and Services Agreement originally dated August 31, 2016 between lnsulet Corporation and ATS Automation Tooling Systems Inc., dated 31 August 2022 |
|---|
| 2023-02-24 | 10-K | 10.52 | First Amendment to the Master Equipment and Services Agreement originally dated August 31, 2016 between lnsulet Corporation and ATS Automation Tooling Systems Inc., dated 31 August 2021 |
|---|
| 2023-02-24 | 10-K | 10.30 | Form of Inventions, Non-Disclosure, Non-Solicitation, Non-Servicing and Non-Competition Agreement (Executive Officers other than Jim Hollingshead and Dan Manea) |
|---|
| 2023-02-22 | 8-K | 10.6 | Consulting Services Agreement by and between the Company and Charles J. Alpuche |
|---|
| 2023-02-22 | 8-K | 10.5 | Annual Incentive Compensation Plan |
|---|
| 2023-02-22 | 8-K | 10.4 | Amended and Restated Executive Severance Plan |
|---|
| 2023-02-22 | 8-K | 10.3 | Form of Performance Stock Unit Agreement |
|---|
| 2023-02-22 | 8-K | 10.2 | Form of Restricted Stock Unit Agreement |
|---|
| 2023-02-22 | 8-K | 10.1 | Form of Non-Qualified Stock Option Agreement |
|---|
| 2023-02-14 | 8-K | 10.1 | Patent Assignment and License Agreement, dated February 9, 2023, between Insulet Corporation, Bigfoot Biomedical, Inc. and Patients Pending, Ltd. |
|---|